Boehringer Ingelheim partners with Science 37 for virtual clinical trials
- by Team ABLE - 04 Jan, 2019
Science 37, virtual clinical trials company, and Boehringer Ingelheim have announced a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials. Science 37 is licensing access to its proprietary software platform, NORA(Network Oriented Research Assistant), which leverages mobile technology and telemedicine capabilities, enabling patients to participate in clinical research studies regardless of their geographical location.
The new collaboration brings together Science 37’s technology for running remote clinical trials and Boehringer Ingelheim’s extensive capabilities in drug discovery and clinical development of novel treatments.
The NORAplatform enables end-to-end virtual or remote clinical trials and adheres to the highest industry quality and regulatory standards. Unlike other mobile health technology companies, Science 37’s remote clinical trial model – called the Metasite – helps researchers engage directly with trial participants through every stage of the trial, from screening and recruitment to telemedicine-based patient care to data lock.
This direct connection online allows for greater retention of patients, increased diversity across trials, and significantly faster recruitment. The patient’s data are sent securely via NORAto researchers who can immediately access information that would otherwise have to be collected by medical personnel through face-to-face interactions at study centers. The platform can also be used to remind patients to take their study medications at the proper time and let researchers know if participants are adhering to the study requirements.
According to the press release, this technology enterprise collaboration agreement between Boehringer Ingelheim and Science 37 positions both companies in the forefront of the global digital health transformation. Science 37’s NORA technology will allow Boehringer Ingelheim to accelerate enrollment and improve the participant experience with decreased patient burden, better patient retention and reduced total trial time. In addition to providing access to NORA, Science 37 will advise on study design, protocol development, and regulatory strategy based on its unique experience in running remote clinical trials. Additionally, Boehringer Ingelheim will have the option to enlist Science 37’s teams to provide a variety of Metasite trial services, including principal investigators, clinical research coordinators, and patient recruitment strategies.
Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide; Science 37’s technology enables patients to remotely participate in clinical studies